SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 7,589.61 |
| Enterprise Value ($M) | 7,394.03 |
| Book Value ($M) | 933.89 |
| Book Value / Share | 8.47 |
| Price / Book | 8.13 |
| NCAV ($M) | 932.71 |
| NCAV / Share | 8.46 |
| Price / NCAV | 8.14 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.10 |
| Return on Assets (ROA) | -0.62 |
| Return on Equity (ROE) | -0.70 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 29.48 |
| Current Ratio | 29.48 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 966.34 |
| Assets | 967.52 |
| Liabilities | 33.63 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -100.83 |
| Net Income | -85.89 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -73.38 |
| Cash from Investing | -179.09 |
| Cash from Financing | 271.38 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Viking Global Investors Lp | 5.10 | -12.18 | |
| 13G | Vanguard Group Inc | 5.38 | ||
| 13G/A | Fmr Llc | 15.00 | 37.37 | |
| 13G | BlackRock Inc. | 7.60 | 432.91 | |
| 13G/A | State Street Corp | 5.73 | 2,222.53 | |
| 13G/A | Millennium Management Llc | 0.40 | -91.64 | |
| 13D/A | Ligand Pharmaceuticals Inc | 4.60 | -40.38 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 777,618 | 3,319,264 | 23.43 | |
| 933,513 | 3,526,931 | 26.47 | |
| 630,245 | 755,779 | 83.39 | |
| 457,239 | 544,392 | 83.99 | |
| 314,398 | 441,756 | 71.17 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| VERU – Veru Inc. | VINC – Vincerx Pharma, Inc. |
| VIRI – Virios Therapeutics, Inc. | VRPX – Virpax Pharmaceuticals, Inc. |
| VSTM – Verastem, Inc. |
Financial data and stock pages provided by
Fintel.io